CHARACTERISTIC FEATURES OF RISK FACTORS IN CHRONIC CEREBRAL ISCHEMIA.
DOI:
https://doi.org/10.5281/zenodo.8313920Abstract
Chronic brain ischemia (SMI) is a specific type of vascular brain pathology caused by gradual progressive diffuse disruption of the blood supply to the brain, as a result of which it is expressed by the development of various defects [4,5]. Stress and depression are a manifestation of SMI. Stress-(derived from English, meaning "stress" - voltage) is a protective reaction of an organism manifested by neuroendocrine and metabolic processes in response to exogenous and endogenous influences.
References
Bilenko M. V. theoretical and experimental foundations of the use of antioxidant therapy to prevent acute ischemic injuries in organs // Bioantioxifiers in the regulation of metabolism in the norm and pathology. M., 1982. Pp. 195-213.
Boldyrev A. A. oxidative stress and brain / / Soros training journal. 2001. No. 7. Pp. 21-27.
Lapin I. P. Neurochemical mosaic of individualization of anxiety and psychopharmacology / / anxiety and obsessions. Moscow: Rams publishing, 1998. Pp. 12-20.
Putilina M. V. possibilities of early drug correction of mental and autonomic disorders in hypertensive encephalopathy / / doctor. 2009. No. 9. Pp. 38-42.
Putilina M. V. neuroprotective therapy of chronic brain ischemia / / physician. 2008. No. 9. Pp. 34-38.
Smirnova I. N., Suslina Z. A., Tanashyan M. M. et al. Antioxidant and neurotrophic effects of cytoflavin in chronic cerebrovascular diseases // Bulletin of the St. Petersburg State Medical Academy. I. I. Mechnikov Academy. 2002. No. 3. Pp. 110-114.
Voronina T. A., Smirnov L. D., Goryainova I. I. mechanism of action and justification of the use of the drug Mexidol in neurology. M., 2000. p. 14.
Fedorova T. N. oxidative stress and protection of the brain from ischemic injury): dis. ... Doc. biol. nauk. M., 2004.12. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo–controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884–895;
Salomova, N. K. (2022). Risk factors for recurrent stroke. Polish journal of science N, 52, 33-35.
Qahharovna, S. N. (2023). Thromboocclusive Lesions of the Bronchocephalic Arteries: Treatment Options and Phytotherapy Options. AMERICAN JOURNAL OF SCIENCE AND LEARNING FOR DEVELOPMENT, 2(2), 41-46.
Salomova Nilufar Kakhorovna//FEATURES OF NEUROREHABILITATION ITSELF DEPENDING ON THE PATHOGENETIC COURSE OF REPEATED STROKES, LOCALIZATION OF THE STROKE FOCUS AND THE STRUCTURE OF NEUROLOGICAL DEFICIT//European Journal of Research Development and Sustainability (EJRDS 11. 8-12. 2022/11
Salomova, N. K. (2022). Risk factors for recurrent stroke. Polish journal of science N, 52, 33-35.
Salomova, N. (2023). TRANSITOR ISCHEMIC ATTACK. International Bulletin of Applied Science and Technology, 3(7), 160-166.
Semaan W., Hergueta T., Bloch J., Charpak Y., Duburcq A., Le Guern M.E., Alquier C., Rouillon F., Cross–sectional study of the prevakence of adjustment disorder with anxiety in general practice.// Encephale. 2001. May–Jun. 27(3). P. 238–44;
Strine T.W., Chapman D.P., Kobau R. et al. Associations of self–reported anxiety symptoms with healh–related quality of life and health behaviors.//Soc Psychyatry Psychiatr Epidemol. 2005. Jun. 40(6). P. 432–8.
Seredenin S.B. Genetic differences on response to emotional stress and tranquilizers // Psychopharmacol & Biol. Narcol. 2003. V. 1–2. P. 494–509.
Marks I.E. Cure and care of neurosis. N.Y.: J.V. Scott Med. Found., 2001. 429 p.
Pollack M.H. Comorbid anxiety and depression // J. Clin. Psychiat. 2005. V. 66, suppl. 8. – P. 22–29.
Nutt D. Imaging receptors in human anxiety // Int. J. Neuropsychopharmacol. 2004. V. 7, suppl. 1. P. 17.
Redoux L. Neurotransmitter basis of anxiety // Anxiety: basic and clinical research. – N.Y.: Hammerworth Press, 2001. P. 36–50.
